Nucleus plus
  • Patient Care
  • About
 
 

09.26.22

Third-party VST Early After allo-HSCT

by ASTCT Science Highlights

Jiang W, Clancy LE, Avdic S, et al. Third-Party CMV- and EBV-Specific T Cells for First Viral Reactivation After Allogeneic Stem Cell Transplant. Blood Advances. 2022; (doi: 10.1182/bloodadvances.2022007103).

Third-party virus-specific T cells (VST) appears safe and results in high rate of viral control and excellent outcomes allogeneic stem cell transplant (HSCT) recipients.  Researchers administered third-party VST in conjunction with antiviral therapy in patients being treated for their first cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection. Overall, 30 HSCT patients (27 with CMV and 3 with EBV) received 1-4 VST infusions an average of 4 days after starting antiviral treatment. The overall viral response and complete response (CR) rates were 100% and 94%, respectively. Nine of the 28 patients who achieved a CR remained virus polymerase chain reaction (PCR) negative during follow up, while 14 were below the quantitation limit. Four patients experienced short bouts of quantifiable reactivation that required no additional treatment, while one patient needed a second infusion following initial CR and then remained PCR negative. The 3 patients who had EBV post-transplant lymphoproliferative disease had sustained CR. The overall rates of acute and chronic graft-versus-host-disease following infusion were 13% and 23%, respectively. No severe infusion-related adverse events were observed. The results correlated virological clearance with recovery of virus-specific immunity, especially CD8+ cells. Non-relapse mortality at 1 year post-HSCT was 10%, while the cumulative incidence of relapse was 7%, overall survival was 88%, and 25 of 27 patients had Eastern Cooperative Oncology Group scores of 0 or 1.


Read more

Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
09.21.23
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
by Alex Kadhim
Dual-split CD38/CD138 CAR targeting for multiple myeloma
09.21.23
Dual-split CD38/CD138 CAR targeting for multiple myeloma
by ASTCT Science Highlights
FLT3-specific UniCAR T-cell therapy against AML
09.19.23
FLT3-specific UniCAR T-cell therapy against AML
by ASTCT Science Highlights
footer divider

ASTCT

American Society for Transplantation
and Cellular Therapy

330 North Wabash Avenue, Suite 2000
Chicago, IL 60611, USA
Phone: (312) 321-6820
Fax: (312) 673-6733

facebook youtube twitter linkedin
Login
Search